

Applicant: Cy A. Stein et al.
Serial No.: 09/753,169
Filed: January 2, 2001
Page 2

Listing of the Claims:

1-4. (Canceled)

5. (Currently Amended) A composition of matter comprising an
An antisense oligonucleotide consisting essentially
comprising 10 or more contiguous bases of the nucleotide
sequence A, C, D, E, F, G, H, I, J, K, L, or M set forth in
any one of [{}]]SEQ ID NOS: 1 and 3-13), respectively
wherein the oligonucleotide is conjugated to a peptide and
wherein the oligonucleotide is complementary to a bcl-xL-
encoding mRNA and inhibits translation thereof.

6-8. (Canceled)

9. (Currently Amended) A composition of matter comprising an
An antisense oligonucleotide consisting of the nucleotide
sequence B—(set forth in SEQ ID NO:2[{}]] wherein the
oligonucleotide is conjugated to a peptide and wherein the
oligonucleotide is complementary to a bcl-xL-encoding mRNA
and inhibits translation thereof.

10-42. (Canceled)

43. (Currently Amended) A ~~pharmaceutical~~ composition comprising
an effective amount of an antisense oligonucleotide of
claim 5 and a pharmaceutically acceptable carrier, wherein
the effective amount is between 0.1 μ M and 10 μ M.

44-47. (Canceled).